查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2004189

癌症支持治疗药物市场：2026-2032年全球市场预测（按药物类别、癌症类型、给药途径、活性原料药成分类型、年龄层、适应症、医疗机构、分销管道和最终用户划分）

Cancer Supportive Care Drugs Market by Drug Class, Cancer Type, Route Of Administration, Originator Type, Age Group, Indication, Care Setting, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，癌症支持治疗药物市场价值将达到 1.5379 亿美元，到 2026 年将增长至 1.6403 亿美元，到 2032 年将达到 2.4697 亿美元，复合年增长率为 7.00%。

主要市场统计数据
基准年 2025 1.5379亿美元
预计年份：2026年 1.6403亿美元
预测年份 2032 2.4697亿美元
复合年增长率 (%) 7.00%

现代肿瘤学越来越需要支持性护理，以维持治疗的连续性并提高患者的生活品质。

癌症支持治疗作为肿瘤治疗的重要补充，其发展持续推进，重点在于维持患者功能、最大限度减少治疗中断，并在整个治疗过程中提升患者的生活品质。化疗技术的进步、对患者生存期的日益关注，以及对支持治疗作为以价值为导向的癌症治疗不可或缺组成部分的认可度不断提高，共同推动了预防或减轻噁心、感染疾病、骨骼併发症、贫血和疼痛等副作用药物的临床和商业性价值的提升。随着治疗方法日益复杂，患者越来越多地在门诊和家庭环境中接受治疗，对有效支持治疗药物及其给药模式的需求日益增长，促使相关人员重新审视药物的可及性、依从性和整合式医疗服务路径。

本研究检验了临床、商业性和交付模式的转变，这种转变正在重新定义支持性照护策略和相关人员的奖励。

癌症支持治疗领域正经历着一场变革性的转变，其驱动力包括临床创新、不断演进的治疗模式以及支付方优先事项的转变，这些因素共同重塑了支持治疗药物的研发、应用和报销方式。新型止吐策略和造血药物的改进正在取得进展，同时，骨骼改良疗法和镇痛方案的多样化也在不断推进。所有这些都反映出人们对治疗相关毒性和生存需求的理解更加深入。这些治疗进展，加上生物相似药和学名药的扩张，迫使传统製药企业优先考虑生命週期管理、患者支持项目和基于价值的合同，以维护其临床和商业性地位。

本研究评估了 2025 年价格政策转变将如何改变支持性照护中所有相关人员的供应链动态、采购重点和取得途径。

美国于2025年实施的政策变化和关税调整，为整个支持性医疗生态系统带来了新的营运和策略考量，其累积影响正波及到生产、分销和医疗服务提供者等各个层面。影响进口活性药物成分、製剂和医疗用品的关税调整，凸显了供应链图谱和服务交付成本分析的重要性。製造商被迫重新评估其筹资策略，与替代供应商建立合作关係，并加快二级供应商的认证流程以降低风险。这种调整正在影响前置作业时间、库存政策以及用于紧急生产能力的资金配置。

整合多维细分可以揭示整个支持性护理市场的临床重点、产品差异化和分销策略。

透过对药物类别、癌症类型、给药途径、原料药成分类型、年龄层、适应症、医疗机构、分销管道和最终用户进行细分，可以建立一个多维地图，从而了解临床需求、商业性机会和营运限制的交汇点。在药物类别内部，止吐药、骨骼调节剂、造血剂和止痛药分别针对不同的临床问题。止吐药类别本身包含多种药理学亚类，例如 5-HT3 受体拮抗剂、NK1 受体拮抗剂和Olanzapine；骨骼调节疗法包括双磷酸盐和 RANKL 抑制剂；造血支持疗法包括促红细胞生成素、骨髓保护剂和血小板生成素促效剂，其中促红细胞生成素的典型製剂包括Darbepoetin和促红血球生成贝泊素。疼痛管理分为非鸦片类药物疗法和鸦片类药物疗法，非鸦片类药物疗法又以对乙酰胺酚、辅助镇痛药和非类固醇消炎剂为特征。

本文比较了各大地区的监管、报销和供应实践，以指导差异化的准入和商业化策略。

区域趋势影响着辅助治疗药物的研发、核准和交付，每个区域都有其独特的法规环境、报销框架和医疗基础设施。在美洲，先进的肿瘤治疗网络和完善的临床试验体系与支付主导的成本控制措施并存，迫使製药公司在创新与可负担性之间寻求平衡，并投资于全面的患者支持和疗效证据。向门诊和居家照护的转变意义重大，推动了对口服製剂、皮下注射剂型以及能够实现远端监测和用药依从性支持的服务的需求。

分析製药公司、专业医疗保健提供者和技术合作伙伴在塑造支持性护理服务方面的策略角色和竞争动态。

关键产业相关人员包括原厂药公司、生物相似药生产商、学名药生产商、专科药房、契约製造组织 (CMO) 和医疗技术提供商，它们各自为支持性医疗价值链带来独特的优势。原厂药公司持续利用临床差异化、缓释製剂和整合式病患服务来保护其现有产品组合。同时，生物相似药和学名药参与企业透过提供更低成本的替代方案并与批发商和专科经销商建立策略合作伙伴关係，加剧了竞争压力。专科药局和整合式医疗服务提供者在协调家庭静脉输液治疗、监测用药依从性和病患教育方面发挥日益重要的作用，成为确保支持性医疗连续性的关键环节。

优先采取与证据生成、供应链韧性、扩大患者支持和灵活合约相关的策略措施，以确保竞争优势。

在不断变化的辅助治疗领域，行业领导者应优先采取一系列切实可行的措施，以确保患者能够获得所需服务，优化治疗效果，并维持商业性的永续性。首先，将可靠的真实世界数据 (RWE) 的创建纳入产品项目，以证明其在临床上能够显着减少住院次数、治疗中断和辅助治疗负担，从而促进支付方的参与，并支持基于价值的协议。其次，透过供应商多元化、尽可能采用近岸外包以及製定紧急库存计画来增强供应链韧性，从而降低政策变革和物流中断带来的风险。第三，拓展病患支援服务，包括经济援助、远端监测和客製化的家庭管理，以提高病患的用药依从性和满意度，同时增强产品差异化优势。

采用混合方法，结合临床文献、专家访谈和交叉检验分析，为支持性照护提供实务见解。

本研究整合了多种方法，旨在整合与支持性治疗相关的临床、营运和商业性见解。为建立实证基础，本研究首先对同侪审查的临床文献、监管指导文件、公共公告和权威临床实践调查方法进行了全面的二次研究。为补充此基准，本研究还开展了一项初步调查，包括对肿瘤科临床医生、专科药剂师、医疗系统处方集决策者、保险公司和行业高管进行结构化访谈，以了解他们对临床未满足需求、获取障碍和商业化策略的实际观点。

本文总结了临床、营运和商业策略的整合如何决定不断发展的支持性护理生态系统中的准入和治疗结果。

这些分析凸显了支持性治疗药物在现代肿瘤治疗实务中的核心作用，它们影响着治疗的连续性、病患体验和医疗资源的利用。临床创新以及向门诊和居家照护模式的转变，对药物製剂、物流和患者支援提出了更高的要求。同时，政策趋势和定价考量也带来了新的营运限制，需要在采购、分销和定价方面进行策略调整。能够整合严谨的真实世界数据、建立稳健的供应链以及以患者为中心的服务模式，从而向保险公司、医疗服务提供者和患者展现价值的利益相关人员者，才能最终获得成功。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：癌症支持治疗药物市场：依药物类别划分

  • 止吐药
    • 5-HT3拮抗剂
    • NK1拮抗剂
    • Olanzapine
  • 骨骼调节药物
    • 双磷酸盐
    • RANKL抑制剂
  • 造血因子
    • 促红细胞生成素
      • Darbepoetin
      • 促红素
    • 骨髓保护剂
    • 血小板生成素受体促效剂
  • 疼痛管理药物
    • 非阿片类药物
      • 乙酰胺酚
      • 辅助止痛药
      • 非类固醇消炎剂（NSAIDs）
    • 阿片类药物

第九章 癌症支持治疗药物市场：依癌症类型划分

  • 骨髓恶性肿瘤
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
    • 骨髓发育不良症候群
  • 固体癌
    • 乳癌
    • 结肠癌
    • 胃肠道癌症
    • 头颈癌
    • 肺癌
    • 卵巢癌
    • 摄护腺癌

第十章：癌症支持治疗药物市场：依给药途径划分

  • 静脉
  • 口服
  • 直肠
  • 皮下
  • 外用
  • 经皮

第十一章 癌症支持治疗药物市场：依原料药类型划分

  • 生物相似药
  • 品牌商品
  • 非专利的

第十二章：癌症支持治疗药物市场：依年龄组别划分

  • 成人版
  • 老年人
  • 儿童

第十三章：癌症支持治疗药物市场：依适应症划分

  • 与骨转移相关的事件
  • 恶病质和食慾不振
  • 癌症疼痛
  • 化疗引起的噁心和呕吐
    • 急性化疗引起的噁心呕吐
    • 特发性/难治性化疗引起的噁心呕吐
    • 延迟性 CINV
  • 腹泻
  • 黏膜炎和口腔炎
  • 骨髓抑制
    • 化疗引起的贫血
    • 化疗引起的嗜中性白血球低下症

第十四章：癌症支持治疗药物市场：依临床环境划分

  • 住院病人
  • 门诊

第十五章：癌症支持治疗药物市场：按分销管道划分

  • 医院药房
  • 邮购及网路药房
  • 零售药房
  • 专科药房

第十六章 癌症支持治疗药物市场：依最终用户划分

  • 门诊手术中心
  • 居家医疗
  • 医院
  • 肿瘤诊所和输液中心

第十七章 癌症支持治疗药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十八章：癌症支持治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十九章 癌症支持治疗药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第二十章：美国：癌症支持治疗药物市场

第21章 中国：癌症支持治疗药物市场

第22章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Acacia Pharma Group Plc
  • Accord Healthcare Limited
  • Amgen Inc.
  • APR Applied Pharma Research SA by Relief Therapeutics Holding AG
  • AstraZeneca plc
  • Coherus BioSciences, Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Ipsen SA
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-450A0628C601

The Cancer Supportive Care Drugs Market was valued at USD 153.79 million in 2025 and is projected to grow to USD 164.03 million in 2026, with a CAGR of 7.00%, reaching USD 246.97 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 153.79 million
Estimated Year [2026] USD 164.03 million
Forecast Year [2032] USD 246.97 million
CAGR (%) 7.00%

Framing the evolving imperative for supportive therapies that preserve treatment continuity and enhance patient quality of life across modern oncology care

Cancer supportive care continues to evolve as a critical complement to oncologic therapy, focusing on preserving patient function, minimizing treatment interruptions, and improving quality of life across the treatment continuum. Advances in anticancer therapeutics, rising emphasis on survivorship, and broader recognition of supportive care as an integral component of value-based oncology care have collectively elevated the clinical and commercial importance of drugs that prevent or mitigate adverse effects such as nausea, infection, bone complications, anemia, and pain. As treatment regimens become more complex and patients increasingly receive therapy in outpatient or home settings, the need for effective supportive agents and delivery models has intensified, prompting stakeholders to re-examine pathways for access, adherence, and integrated care delivery.

Regulatory attention and payer scrutiny have shifted the conversation from episodic symptom control to longitudinal management strategies that reduce hospitalizations and enable continued cancer-directed therapy. Meanwhile, technological enablers such as telemedicine, remote monitoring, and digital adherence tools are being woven into supportive care pathways to detect complications early and to triage interventions. These developments are influencing clinical practice guidelines, hospital formularies, and procurement strategies, while simultaneously shaping expectations among patients and caregivers for a higher standard of symptom management. Consequently, supportive care drugs are no longer ancillary commodities but constitute strategic assets in optimizing treatment outcomes and sustaining healthcare system efficiencies.

Examining the clinical, commercial, and delivery model transformations that are redefining supportive care strategies and stakeholder incentives

The landscape of cancer supportive care has undergone transformative shifts driven by clinical innovation, delivery model changes, and evolving payer priorities that collectively reshape how supportive medicines are developed, adopted, and reimbursed. Novel antiemetic strategies and refinements in hematopoietic agents are emerging alongside an expanding portfolio of bone-modifying therapies and diversified analgesic options, all of which reflect a more nuanced understanding of treatment-related toxicities and survivorship needs. These therapeutic advances are complemented by an expansion of biosimilars and generics that force incumbent manufacturers to prioritize lifecycle management, patient support programs, and value-based contracting to defend clinical and commercial positioning.

Concurrent shifts in care delivery have profound implications. An acceleration of outpatient infusion, homecare services, and remote monitoring has prompted manufacturers and providers to redesign packaging, dosing regimens, and adherence support to accommodate decentralized treatment environments. Payer emphasis on outcomes and cost containment is incentivizing real-world evidence generation and performance-based agreements, which in turn influence clinical guideline adoption and formulary decisions. Supply chain resilience and manufacturing flexibility have become strategic priorities in light of geopolitical pressures and episodic disruptions, increasing interest in diversified sourcing, nearshoring, and capacity partnering with contract manufacturers. Taken together, these shifts signal a more integrated, multidisciplinary approach to supportive care that aligns clinical efficacy with operational feasibility and economic sustainability.

Assessing how tariff policy shifts in 2025 altered supply chain dynamics, procurement priorities, and access pathways across supportive care stakeholders

Policy changes and tariff considerations introduced in the United States in 2025 have injected a new set of operational and strategic calculations across the supportive care ecosystem, with cumulative impacts felt at the manufacturing, distribution, and provider levels. Tariff adjustments affecting imported active pharmaceutical ingredients, finished formulations, and medical supplies have increased the emphasis on supply chain mapping and cost-to-serve analysis. Manufacturers have been prompted to reassess sourcing strategies, pursue alternative supplier relationships, and accelerate qualification of secondary suppliers to mitigate exposure. This recalibration has implications for lead times, inventory policies, and capital allocation for contingency manufacturing capacity.

These policy-induced cost pressures have reverberated through distribution channels and procurement cycles, elevating negotiation intensity between manufacturers, distributors, and payers. Health systems and specialty pharmacies have intensified their focus on formulary optimization and total cost-of-care calculations to preserve access while managing budgets. At the clinical interface, providers have become more attentive to therapeutic equivalence and to opportunities for substituting lower-cost generics or biosimilars where clinically appropriate. Patient support mechanisms have also been affected as companies re-evaluate copay assistance programs and logistical support for home administration to ensure affordability and continuity of therapy.

In response to tariff-driven uncertainty, some stakeholders have advocated for policy engagement and collaborative solutions, such as tariff exemptions for critical medical inputs, incentives for domestic manufacturing, and streamlined regulatory pathways for rapid supplier qualification. These strategies aim to balance the goals of national industrial policy with the imperative to maintain patient access and clinical quality. Looking ahead, organizations that proactively adapt procurement, contractual frameworks, and patient support models will be better positioned to navigate sustained policy variability while safeguarding treatment continuity for vulnerable patient populations.

Integrating multi-dimensional segmentation to illuminate clinical priorities, product differentiation, and distribution strategies across supportive care markets

Segmentation across drug class, cancer type, route of administration, originator type, age group, indication, care setting, distribution channel, and end user creates a multidimensional map for understanding where clinical needs intersect with commercial opportunity and operational constraints. Within drug class, antiemetics, bone-modifying agents, hematopoietic agents, and pain management agents each address distinct clinical problems; the antiemetic category itself includes pharmacologic subclasses such as 5-HT3 antagonists, NK1 antagonists, and olanzapine, while bone-modifying therapies encompass bisphosphonates and RANKL inhibitors. Hematopoietic support spans erythropoiesis stimulating agents, myeloprotection agents, and thrombopoietin receptor agonists, and erythropoiesis stimulating agents are characterized by formulations such as darbepoetin and epoetin. Pain management divides into non-opioid and opioid approaches, with non-opioids further characterized by acetaminophen, adjuvant analgesics, and nonsteroidal anti-inflammatory drugs.

Cancer type segmentation distinguishes hematologic malignancies and solid tumors, with hematologic categories covering leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes, while solid tumors include breast, colorectal, gastrointestinal, head and neck, lung, ovarian, and prostate cancers, each of which presents unique supportive care priorities and guideline-driven interventions. Route of administration intersects with care setting considerations, spanning intravenous, oral, rectal, subcutaneous, topical, and transdermal modalities, and prompting different patient education, adherence, and logistics needs. Originator type-biosimilar, branded, and generic-shapes pricing dynamics and contracting strategies, while age-group segmentation across adult, geriatric, and pediatric populations demands tailored dosing, safety monitoring, and caregiver support.

Indication-based segmentation addresses complications such as bone metastases related events, cachexia and anorexia, cancer pain, chemotherapy-induced nausea and vomiting with its acute, breakthrough/refractory, and delayed subcategories, diarrhea, mucositis and stomatitis, and myelosuppression including chemotherapy-induced anemia and neutropenia; each indication imposes specific efficacy, safety, and delivery expectations. Distribution channel and end-user segmentation illuminate commercial pathways, with hospital pharmacies, mail-order and online pharmacies, retail pharmacies, and specialty pharmacies interacting with ambulatory surgery centers, homecare settings, hospitals, and oncology clinics and infusion centers. Integrating these segmentation lenses enables stakeholders to prioritize product development, align patient support programs, and design distribution strategies that reflect clinical workflows and payer requirements.

Comparing the regulatory, reimbursement, and delivery realities across major regions to guide differentiated access and commercialization strategies

Regional dynamics shape how supportive care drugs are developed, approved, and delivered, with each geography presenting distinct regulatory environments, reimbursement paradigms, and care delivery infrastructures. In the Americas, advanced oncology care networks and strong clinical trial ecosystems coexist with payer-driven cost containment, driving manufacturers to balance innovation with affordability and to invest in robust patient support and outcomes evidence. Shifts toward outpatient and home-based care are pronounced, amplifying demand for oral formulations, subcutaneous options, and services that enable remote monitoring and adherence support.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and diverse market access pathways require differentiated strategies that account for national reimbursement rules, tendering mechanisms, and varying levels of healthcare infrastructure. Manufacturers often pursue regionally tailored evidence generation and pricing strategies to secure formulary inclusion, and partnerships with regional distributors and specialty pharmacies are common to bridge logistical gaps and enhance reach. In the Asia-Pacific region, rapid healthcare modernization, expanding oncology service capacity, and growing attention to biosimilar adoption create both opportunities and complexities. Regulatory harmonization efforts coexist with country-specific procurement models, and manufacturers are incentivized to develop flexible supply arrangements and locally relevant patient support services to accelerate uptake and sustain access amid evolving payer expectations.

Profiling the strategic roles and competitive moves of manufacturers, specialty providers, and technology partners shaping supportive care delivery

Key industry participants span originator pharmaceutical companies, biosimilar manufacturers, generic producers, specialty pharmacies, contract manufacturing organizations, and healthcare technology providers, each contributing distinct capabilities to the supportive care value chain. Originator firms continue to leverage clinical differentiation, extended-release formulations, and integrated patient services to defend established franchises, while biosimilar and generic entrants intensify competitive pressure by offering lower-cost alternatives and by pursuing strategic partnerships with wholesalers and specialty distributors. Specialty pharmacies and integrated care providers play an increasingly important role in coordinating home infusion, adherence monitoring, and patient education, serving as critical touchpoints for ensuring continuity of supportive therapy.

Contract manufacturing and outsourcing partners have expanded capacity to meet demand for flexible production and regulatory compliance, enabling companies to respond more rapidly to supply disruptions and to local content requirements. Technology providers supplying remote monitoring, telehealth platforms, and digital adherence tools are forging collaborations with manufacturers and providers to support decentralized care models. Across this ecosystem, leading organizations are distinguishing themselves through investments in real-world evidence, comprehensive patient support programs that address affordability and logistics, and value-based contracting approaches that align reimbursement with clinical outcomes. These strategic moves reflect a broader emphasis on integrated care pathways, where drug efficacy must be matched by delivery capabilities and demonstrable impact on patient-relevant endpoints.

Prioritizing strategic actions on evidence generation, supply chain resilience, patient support expansion, and flexible contracting to secure competitive advantage

Industry leaders should prioritize a set of actionable initiatives to secure access, optimize patient outcomes, and sustain commercial viability in a changing supportive care environment. First, embedding robust real-world evidence generation into product programs will facilitate payer engagement and support value-based agreements by demonstrating clinically meaningful reductions in hospitalizations, treatment interruptions, and supportive care burden. Second, strengthening supply chain resilience through supplier diversification, nearshoring where feasible, and contingency inventory planning will reduce vulnerability to policy shifts and logistic disruptions. Third, expanding patient support services that encompass financial navigation, remote monitoring, and coordinated home administration will improve adherence and patient satisfaction while reinforcing differentiation.

In parallel, organizations should adopt flexible pricing and contracting frameworks that account for total cost of care and enable outcome-based arrangements with payers and providers. Product teams must align formulation development and packaging innovations with the realities of outpatient and home care to enhance usability and safety. Strategic alliances with specialty pharmacies, homecare providers, and technology vendors can accelerate adoption of decentralized care models and provide seamless patient experiences. Executing these recommendations requires cross-functional coordination across commercial, medical, regulatory, and supply chain teams, and a willingness to pilot new commercial models in partnership with payers and provider systems to generate the evidence and operational learnings necessary for scale.

Explaining the mixed-methods approach that combines clinical literature, expert interviews, and cross-validated analysis to produce actionable supportive care insights

This research integrates a multi-method approach to synthesize clinical, operational, and commercial insights relevant to supportive care therapeutics. The methodology begins with comprehensive secondary research drawn from peer-reviewed clinical literature, regulatory guidance documents, public policy announcements, and authoritative clinical practice guidelines to establish an evidence-based foundation. This baseline was complemented by primary research consisting of structured interviews with oncology clinicians, specialty pharmacists, health system formulary decision-makers, payers, and industry executives to capture frontline perspectives on clinical unmet needs, access barriers, and commercialization tactics.

Analytical methods included qualitative thematic analysis to surface recurring themes and strategic priorities, and cross-validation using triangulation across data sources to ensure consistency and reduce bias. Segmentation frameworks were constructed by mapping therapeutic classes, clinical indications, administration routes, and care settings to real-world care pathways, allowing for scenario analysis of distribution and access models. Validation steps involved iterative review with independent clinical advisors and supply chain specialists to refine assumptions about operational feasibility and to corroborate strategic interpretations. Where applicable, regulatory and policy analyses were incorporated to contextualize potential impacts on procurement, manufacturing, and patient access.

Summarizing how integrated clinical, operational, and commercial strategies will determine access and outcomes in the evolving supportive care ecosystem

The cumulative analysis underscores that supportive care drugs are central to contemporary oncology practice, influencing treatment continuity, patient experience, and healthcare resource utilization. Clinical innovation, coupled with shifts in care delivery toward outpatient and home-based models, has elevated requirements for formulations, logistics, and patient support. Concurrently, policy developments and tariff considerations have introduced new operational constraints that necessitate strategic adaptation across sourcing, distribution, and pricing. Stakeholders that succeed will be those that integrate rigorous real-world evidence, resilient supply chains, and patient-centric service models to demonstrate value to payers, providers, and patients.

Looking ahead, the convergence of clinical, commercial, and operational trends points to a future in which supportive care strategies are tightly aligned with broader oncology objectives: enabling sustained delivery of cancer-directed therapies, mitigating adverse events, and optimizing total cost of care. Organizations that proactively reconfigure their portfolios, partnerships, and evidence-generation strategies to reflect decentralized care realities and evolving reimbursement expectations will be best positioned to deliver meaningful improvements in patient outcomes while sustaining long-term competitiveness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Supportive Care Drugs Market, by Drug Class

  • 8.1. Antiemetics
    • 8.1.1. 5-HT3 Antagonists
    • 8.1.2. NK1 Antagonists
    • 8.1.3. Olanzapine
  • 8.2. Bone-Modifying Agents
    • 8.2.1. Bisphosphonates
    • 8.2.2. RANKL Inhibitors
  • 8.3. Hematopoietic Agents
    • 8.3.1. Erythropoiesis Stimulating Agents
      • 8.3.1.1. Darbepoetin
      • 8.3.1.2. Epoetin
    • 8.3.2. Myeloprotection Agents
    • 8.3.3. Thrombopoietin Receptor Agonists
  • 8.4. Pain Management Agents
    • 8.4.1. Non-Opioids
      • 8.4.1.1. Acetaminophen
      • 8.4.1.2. Adjuvant Analgesics
      • 8.4.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.4.2. Opioids

9. Cancer Supportive Care Drugs Market, by Cancer Type

  • 9.1. Hematologic Malignancies
    • 9.1.1. Leukemias
    • 9.1.2. Lymphomas
    • 9.1.3. Multiple Myeloma
    • 9.1.4. Myelodysplastic Syndromes
  • 9.2. Solid Tumors
    • 9.2.1. Breast Cancer
    • 9.2.2. Colorectal Cancer
    • 9.2.3. Gastrointestinal Cancers
    • 9.2.4. Head And Neck Cancer
    • 9.2.5. Lung Cancer
    • 9.2.6. Ovarian Cancer
    • 9.2.7. Prostate Cancer

10. Cancer Supportive Care Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Rectal
  • 10.4. Subcutaneous
  • 10.5. Topical
  • 10.6. Transdermal

11. Cancer Supportive Care Drugs Market, by Originator Type

  • 11.1. Biosimilar
  • 11.2. Branded
  • 11.3. Generic

12. Cancer Supportive Care Drugs Market, by Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Cancer Supportive Care Drugs Market, by Indication

  • 13.1. Bone Metastases Related Events
  • 13.2. Cachexia & Anorexia
  • 13.3. Cancer Pain
  • 13.4. Chemotherapy-Induced Nausea & Vomiting
    • 13.4.1. Acute CINV
    • 13.4.2. Breakthrough/Refractory CINV
    • 13.4.3. Delayed CINV
  • 13.5. Diarrhea
  • 13.6. Mucositis And Stomatitis
  • 13.7. Myelosuppression
    • 13.7.1. Chemotherapy-Induced Anemia
    • 13.7.2. Chemotherapy-Induced Neutropenia

14. Cancer Supportive Care Drugs Market, by Care Setting

  • 14.1. Inpatient
  • 14.2. Outpatient

15. Cancer Supportive Care Drugs Market, by Distribution Channel

  • 15.1. Hospital Pharmacies
  • 15.2. Mail-Order And Online Pharmacies
  • 15.3. Retail Pharmacies
  • 15.4. Specialty Pharmacies

16. Cancer Supportive Care Drugs Market, by End User

  • 16.1. Ambulatory Surgery Centers
  • 16.2. Homecare Settings
  • 16.3. Hospitals
  • 16.4. Oncology Clinics And Infusion Centers

17. Cancer Supportive Care Drugs Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Cancer Supportive Care Drugs Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Cancer Supportive Care Drugs Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Cancer Supportive Care Drugs Market

21. China Cancer Supportive Care Drugs Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abbott Laboratories
  • 22.6. Acacia Pharma Group Plc
  • 22.7. Accord Healthcare Limited
  • 22.8. Amgen Inc.
  • 22.9. APR Applied Pharma Research S.A. by Relief Therapeutics Holding AG
  • 22.10. AstraZeneca plc
  • 22.11. Coherus BioSciences, Inc.
  • 22.12. Daiichi Sankyo Company, Limited
  • 22.13. Dr. Reddy's Laboratories Ltd.
  • 22.14. F. Hoffmann-La Roche Ltd.
  • 22.15. Fresenius Kabi AG
  • 22.16. Fresenius SE & Co. KGaA
  • 22.17. GlaxoSmithKline plc
  • 22.18. Helsinn Healthcare SA
  • 22.19. Heron Therapeutics, Inc.
  • 22.20. Ipsen S.A.
  • 22.21. Johnson & Johnson Services, Inc.
  • 22.22. Lupin Limited
  • 22.23. Novartis AG
  • 22.24. Pfizer Inc.
  • 22.25. Sanofi S.A.
  • 22.26. Teva Pharmaceutical Industries Ltd.
  • 22.27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION